Slide 1: 2026 First quarter trading statement
2026 First quarter trading statement April 2026
Slide 2: Disclaimer
Disclaimer This presentation contains certain statements that are, or may be deemed These forward-looking statements and views may be based on a number to be, “forward-looking statements” (including for purposes of the safe of assumptions and, by their nature, involve known and unknown risks, harbor
Slide 3: Brian McNamara, CEO – 2026 First quarter results
Brian McNamara CEO 2026 First quarter results
Slide 4: Navigated a challenging market: 2.2% organic revenue growth with soft cold and flu season
Navigated a challenging market: 2.2% organic revenue growth with soft cold and flu season impacting growth by c.130bps Strong performance across Oral Health with innovation-led premiumisation and geographic expansion North America returned to growth with strong momentum in Oral Health and VMS Produc
Slide 5: First quarter 2026 revenue
First quarter 2026 revenue £2.9bn 2.2% 2.4% /(0.2)% Q1 revenue Organic revenue growth1 Price / Volume Mix Navigated a challenging market with weak cold and flu season having a c.130bps impact Delivering on capital allocation priorities • Completed c.36% of £500m share buyback allocated North America
Slide 6: Dawn Allen, CFO – 2026 First quarter results
Dawn Allen CFO 2026 First quarter results
Slide 7: Q1 2026 organic revenue growth: +2.2%
Q1 2026 organic revenue growth : +2.2% 1 ORG1 (0.0)% +2.2% Organic revenue growth impacted by Net M&A weak cold and flu season (c. 130bps (2.1)% 2.4% impact) and performance in Brazil £2,853m (0.2)% £2,857m Translational foreign exchange impact Volume Translational reflects year-on-year movement in
Slide 8: Global portfolio delivering growth
Global portfolio delivering growth Organic. Q1 2026 Revenue. revenue growth1 £m % Oral Health 932 8.3 VMS 414 1.7 Pain Relief 654 (0.3) Respiratory Health 499 (3.4) Digestive Health 239 (0.4) Therapeutic Skin Health and Other 119 3.0 TOTAL 2,857 2.2 1. Definition/reconciliation of IFRS to non-IFRS r
Slide 9: North America
North America 33% of Q1 2026 Revenue Q1 performance: £932m • Double digit growth in Oral Health • Mid-single digit growth in VMS with Centrum Q1 2026 Revenue growing high-single digit • Across OTC, performance impacted by weaker cold and flu season 1.0% 3.7% (2.7)% Organic growth1 Price Volume / mix
Slide 10: EMEA & LATAM
EMEA & LATAM 43% of Q1 2026 Revenue Q1 performance: £1,240m • Modest revenue growth in Europe with strength in Oral Health partly offset by weakness in cold and flu in Central and Eastern Europe Q1 2026 Revenue • Middle East & Africa up high-single digit supported by innovation; not significantly im
Slide 11: APAC
APAC 24% of Q1 2026 Revenue Q1 performance: £685m • China grew mid-single digit with strength in e-comm and innovation Q1 2026 Revenue • India up double digit with excellent in market execution across Oral Health • Significant impact from weak cold and flu season across 4.0% 0.3% 3.7% region Organic
Slide 12: 2026 guidance
2026 guidance Organic revenue growth1 of 3%-5% High-single digit adjusted operating profit growth2 Other modelling considerations Net Interest, Tax, and Translational Foreign non-controlling interest Exchange • Net interest cost expected to be • A broadly neutral foreign c.£255m exchange translation
Slide 13: Navigated a challenging market: 2.2% organic revenue growth with soft cold and flu season
Navigated a challenging market: 2.2% organic revenue growth with soft cold and flu season impacting growth by c.130bps Strong performance across Oral Health with innovation-led premiumisation and geographic expansion North America returned to growth with strong momentum in Oral Health and VMS Produc
Slide 14: Appendix
Appendix
Slide 15: Glossary
Glossary Organic revenue growth Organic revenue represents revenue, as determined under IFRS, but excluding the impact of − Prior year and current year organic revenue growth exclude revenue attributable to divestments, acquisitions, manufacture and supply agreements (MSAs) relating to divestments M
Slide 16: Respiratory Health impacted by cold and flu season
Respiratory Health impacted by cold and flu season Weekly market cold and flu (million units) 50 C&F season 45 2024-25 40 2025-26 35 30 25 20 15 Winter season Off season 10 Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Source: Local week data, 10 markets (US, FR, UK, DE, IT, RU, PL, SK, CZ and HU)
Slide 17: Historic quarterly growth across the categories
Historic quarterly growth across the categories Organic revenue growth1 2025 2026 Q1 Q2 Q3 Q4 FY Q1 Oral Health 6.6% 8.7% 6.9% 9.3% 7.9% 8.3% VMS 0.9% 0.9% 4.9% 1.2% 1.9% 1.7% Pain Relief 2.6% 2.5% 3.7% 0.5% 2.3% (0.3)% Respiratory Health 0.7% (2.0)% (1.8)% (4.6)% (1.9)% (3.4)% Digestive Health 2.3%
Slide 18: Reconciliation of Q1 organic growth
Reconciliation of Q1 organic growth Product Categories Therapeutic Oral Pain Respiratory Digestive Skin Health 2026 vs 2025 (%) Health VMS Relief Health Health & Other Total Revenue Growth 5.9 (0.5) (1.1) (5.0) (5.9) 1.7 0.1 Organic Adjustments - - - - - 0.4 0.0 Effect of Exchange Rates 2.4 2.2 0.8
Slide 19: Q1 2026 results
Q1 2026 results Jo Russell Rakesh Patel Head of Investor Relations Director of Investor Relations Joanne.c.Russell@Haleon.com Rakesh.x.Patel@Haleon.com +44 7787 392441 +44 7552 484646